‘A fighting chance’: Why Mirxes chose Hong Kong over Singapore for its IPO

Chief executive Dr Zhou Lihan explained, "If we raise at a lower valuation that doesn’t give us enough ammunition, it actually defeats our entire purpose of fundraising."

https://bt.sg/5FCc

Meanwhile, SGX amends life sciences listing rules to make revenue exemption explicit: https://bt.sg/5FCq